<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXALIPLATIN</span><br/>(ox-a-li-pla'tin)<br/><span class="topboxtradename">Eloxatin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg vials; 5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Oxaliplatin forms inter- and intra-strand DNA cross-links. These cross-links inhibit DNA replication and transcription. The
         cytotoxicity of oxaliplatin is cell-cycle nonspecific.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antitumor activity of oxaliplatin in combination with 5-fluorouracil (5-FU) has antiproliferative activity against colon carcinoma
         that is greater than either compound alone. In addition it is also used in combination with leucovorin (LV) along with the
         5-FU for greater effectiveness.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic cancer of colon and rectum.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of known allergy to oxaliplatin or other platinum compounds; myelosuppression; pregnancy (category D); lactation.
         Safety and effectiveness in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, because clearance of ultrafilterable platinum is decreased in mild, moderate, and severe renal impairment;
         hepatic impairment.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Colon or Rectal Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 85 mg/m<sup>2</sup> infused over 120 min once every 2 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Premedication with an antiemetic is recommended.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> NEVER reconstitute with NS or any solution containing chloride. Reconstitute the 50 mg vial or the 100 mg vial by adding 10
                  mL or 20 mL, respectively, of sterile water for injection or D5W. MUST further dilute in 250500 mL of D5W for infusion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Do NOT use needles or infusion sets containing aluminum parts. Flush infusion line with D5W before and after administration
                  of any other concomitant medication. Give over 120 min with frequent monitoring of the IV insertion site. Discontinue at the
                  first sign of extravasation and restart IV in a different site.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <span class="classification">chloride-containing solutions</span>, <span class="classification">alkaline solutions</span>, including <b>sodium bicarbonate,</b> <b>5-fluorouracil (5-FU)</b> <span class="incompattype">Y-site:</span> <span class="classification">alkaline solutions</span>, including <b>sodium bicarbonate,</b> <b>5-fluorouracil (5-FU).</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solution up to 24 h under refrigeration at 2°8° C (36°46° F). After final
            dilution, the IV solution may be stored for 6 h at room temperature [20°25° C (68°77° F)]
            or up to 24 h under refrigeration.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Fever, edema, pain,</span> allergic reaction, arthralgia, rigors. <span class="typehead">CNS:</span> <span class="speceff-common">Fatigue, neuropathy, headache,</span> dizziness, insomnia. <span class="typehead">CV:</span> Chest pain. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea, nausea, vomiting, anorexia, stomatitis, constipation, abdominal pain,</span> reflux, dyspepsia, taste perversion, mucositis, flatulence. <span class="typehead">Hematologic:</span> <span class="speceff-common">Anemia, leukopenia, thrombocytopenia,</span> neutropenia, thromboembolism. <span class="typehead">Metabolic:</span> Hypokalemia, dehydration. <span class="typehead">Respiratory:</span> <span class="speceff-common">Dyspnea, cough,</span> rhinitis, pharyngitis, epistaxis, hiccup. <span class="typehead">Skin:</span> Flushing, rash, alopecia, injection site reaction. <span class="typehead">Urogenital:</span> Dysuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">aminoglycosides</span>, <b>amphotericin B,</b> <b>vancomycin,</b> and other <b>nephrotoxic drugs</b> may increase risk of renal failure. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> &gt;90% protein bound. <span class="typehead">Metabolism:</span> Rapid and extensive non-enzymatic biotransformation. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 391 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypersensitivity (e.g., rash, urticaria, erythema, pruritis; rarely, bronchospasm and hypotension). Discontinue
            drug and notify physician if any of these occur.
         </li>
<li>Monitor insertion site. Extravasation may cause local pain and inflammation that may be severe and lead to complications,
            including necrosis.
         </li>
<li>Monitor for S&amp;S of coagulation disorders including GI bleeding, hematuria, and epistaxis.</li>
<li>Monitor for S&amp;S of peripheral neuropathy (e.g., paresthesia, dysesthesia, hypoesthesia in the hands, feet, perioral area,
            or throat, jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and chest pressure). Symptoms may be precipitated or
            exacerbated by exposure to cold temperature or cold objects.
         </li>
<li>Lab tests: Before each administration cycle, monitor WBC count with differential, hemoglobin, platelet count, and blood chemistries
            (including ALT, AST, bilirubin, and creatinine). Monitor baseline and periodic renal functions.
         </li>
<li>Do not apply ice to oral mucous membranes (e.g., mucositis prophylaxis) during the infusion of oxaliplatin as cold temperature
            can exacerbate acute neurological symptoms.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use effective methods of contraception while receiving this drug.</li>
<li>Avoid cold drinks, use of ice, and cover exposed skin prior to exposure to cold temperature or cold objects.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following to a health care provider: difficulty writing, buttoning, swallowing, walking; numbness, tingling
            or other unusual sensations in extremities; non-productive cough or shortness of breath; fever, particularly if associated
            with persistent diarrhea or other evidence of infection.
         </li>
<li>Report promptly S&amp;S of a bleeding disorder such as black tarry stool, coke-colored or frankly bloody urine, bleeding from
            the nose or mucous membranes.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>